Enoxaparin versus tinzaparin in non st segment elevation acute coronary syndromes the evet trial
This presentation is the property of its rightful owner.
Sponsored Links
1 / 7

Enoxaparin versus Tinzaparin in Non-ST-segment Elevation Acute Coronary Syndromes: The EVET Trial PowerPoint PPT Presentation


  • 71 Views
  • Uploaded on
  • Presentation posted in: General

Enoxaparin versus Tinzaparin in Non-ST-segment Elevation Acute Coronary Syndromes: The EVET Trial. Michalis LK, Katsouras CS, Papamichael N, Adamides K, Naka KK, Goudevenos J, Sideris DA. Am Heart J. 2003 Aug;146(2):304-10. EVET.

Download Presentation

Enoxaparin versus Tinzaparin in Non-ST-segment Elevation Acute Coronary Syndromes: The EVET Trial

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -

Presentation Transcript


Enoxaparin versus tinzaparin in non st segment elevation acute coronary syndromes the evet trial

Enoxaparin versus Tinzaparin in Non-ST-segment Elevation Acute Coronary Syndromes:The EVET Trial

Michalis LK, Katsouras CS, Papamichael N, Adamides K, Naka KK, Goudevenos J, Sideris DA.

Am Heart J. 2003 Aug;146(2):304-10


Enoxaparin versus tinzaparin in non st segment elevation acute coronary syndromes the evet trial

EVET

438 patients with non-ST-segment elevation acute coronary syndromes (NSTACS)

Single center, open-label randomized trial

  • Enoxaparin

  • Subcutaneous 100 IU/kg 2x daily

  • Equivalent to 1 mg/kg 2x daily

  • (n = 220)

  • Tinzaparin

  • 175 IU/kg once daily

  • (n = 218)

  • Endpoints:

    • Primary – Composite of recurrent angina, MI or death at day 7

    • Secondary – Primary endpoint at day 30 and the individual events at days 7 and 30

Am Heart J 2003;146(2):304-10


Evet primary composite endpoint at day 7

EVET: Primary Composite Endpoint at Day 7

Death, MI, Recurrent Angina

p=0.015

%

Am Heart J 2003;146(2):304-10


Evet components of composite endpoint at day 7

EVET: Components of Composite Endpoint at Day 7

Recurrent Angina

p<0.05

Death

p=NS

MI

p=NS

%

Am Heart J 2003;146(2):304-10


Evet primary composite endpoint at day 30

EVET: Primary Composite Endpoint at Day 30

Death, MI, Recurrent Angina

p=0.012

%

Am Heart J 2003;146(2):304-10


Evet components of composite endpoint day 30

EVET: Components of Composite Endpoint Day 30

Recurrent Angina

p<0.05

Death

p=NS

MI

p<0.05

%

Am Heart J 2003;146(2):304-10


Evet revascularization at day 7 and day 30

EVET: Revascularization at Day 7 and Day 30

Day 30

p=0.019

Day 7

p=0.010

%

Am Heart J 2003;146(2):304-10


  • Login